Back to results
US 2021/0171552 A1Published application
Phosphoantigen prodrug compounds
AssigneesUniversity College Cardiff Consultants Limited, The University of Birmingham
InventorsYoucef Mehellou, Benjamin Willcox
Life of this patent
Estimating the term…
Abstract
The invention relates to a compound of General Formula (I): wherein R1, R2, R3, R4 and R5 are as defined herein. Compounds and compositions comprising the same exhibit high serum stability and potent activation of the γδ T-cell immune response, so are suitable for use in immunotherapy. The invention also relates to methods of immunotherapy using the compounds of General Formula (I).
Claims28
A compound according to General Formula (I) including all tautomers thereof:
- wherein R1 and R2 each independently represents an amino acid ester radical according to General Formula (II) or an aryloxy radical according to General Formula (III):
- wherein R6 represents H, or a saturated or unsaturated and optionally substituted hydrocarbon chain;
- R7 represents a saturated or unsaturated and optionally substituted hydrocarbon chain;
- and
- R8 represents an optionally substituted C5-25 aryl or a 5 to 25 membered heteroaryl group;
- R3 represents an optionally substituted C2-20 alkyl, C4-20 alkenyl or C2-20 alcohol radical;
- and
- each of R4 and R5 independently represent H or halo;
- or a salt thereof.
6 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.